Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Kura Oncology Inc

Healthcare US KURA

8.77USD
0.12(1.33%)

Last update at 2026-06-04T20:07:00Z

Day Range

8.649.05
LowHigh

52 Week Range

7.4124.17
LowHigh

Fundamentals

  • Previous Close 8.65
  • Market Cap1633.69M
  • Volume2091275
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-182.81299M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -135.84000M -130.46600M -89.62500M -63.14000M -60.44700M
Minority interest - - - - -
Net income -136.06900M -129.90800M -89.43100M -63.14000M -60.44700M
Selling general administrative 47.05M 46.54M 31.50M 19.65M 16.10M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.76M 0.56M 0.19M 0.00000M 0.01000M
Ebit -140.62400M -131.81600M -92.09300M -63.14000M -62.89300M
Ebitda -139.86500M -131.25800M -91.89900M -67.47900M -62.88300M
Depreciation and amortization 0.76M 0.56M 0.19M - 0.01000M
Non operating income net other 4.25M 1.21M 2.85M 4.92M 3.41M
Operating income -140.62400M -131.81600M -92.09300M -67.47900M -62.88300M
Other operating expenses 139.87M 131.26M 91.90M 67.48M 62.88M
Interest expense 0.23M 0.41M 0.58M 0.58M 0.97M
Tax provision - - - - -
Interest income 4.25M 1.21M 2.80M 4.67M 3.17M
Net interest income 4.03M 0.79M 2.22M 4.09M 2.20M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.23M -0.55800M -0.19400M -4.91900M 3.41M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 139.87M 131.26M 91.90M 67.48M 62.88M
Cost of revenue - - - - 0.00000M
Total other income expense net 4.78M 1.35M 2.47M 4.34M 2.44M
Discontinued operations - - - - -
Net income from continuing ops -135.84000M -130.46600M -89.62500M -63.14000M -60.44700M
Net income applicable to common shares -135.84000M -130.46600M -89.62500M -63.14000M -60.44700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 448.94M 456.31M 534.05M 647.21M 241.97M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.72M 8.44M 4.33M 3.97M 2.68M
Total liab 51.66M 36.03M 27.44M 36.31M 23.19M
Total stockholder equity 397.27M -568.80800M -432.96800M -302.50200M -212.87700M
Deferred long term liab - - - - -
Other current liab 31.46M 20.21M 16.96M 18.18M 11.79M
Common stock 0.00700M 0.00700M 0.00700M 0.00700M 0.00500M
Capital stock 0.00700M 0.00700M 0.00700M 0.00700M 0.00500M
Retained earnings -721.43900M -568.80800M -432.96800M -302.50200M -212.87700M
Other liab - 0.27M 0.38M 0.40M 0.38M
Good will - - - - -
Other assets - 3.50M 3.52M 7.90M 2.09M
Cash 37.32M 51.80M 90.67M 325.49M 26.14M
Cash and equivalents - - - - -
Total current liabilities 35.26M 24.06M 22.45M 26.02M 15.56M
Current deferred revenue - - - - -
Net debt -20.11800M -37.77800M -83.79700M -310.51600M -18.63500M
Short term debt 1.51M 2.32M 2.26M 5.09M 0.25M
Short long term debt - - - 3.00M 0.25M
Short long term debt total 17.20M 14.02M 6.88M 14.98M 7.50M
Other stockholder equity 1119.98M 8.03M 1.78M -0.05300M -0.33600M
Property plant equipment - 2.54M 2.67M 2.02M 0.28M
Total current assets 432.48M 446.43M 522.29M 637.29M 239.60M
Long term investments - - - - -
Net tangible assets - 420.28M 506.61M 610.90M 218.78M
Short term investments 386.64M 386.18M 427.29M 307.83M 210.76M
Net receivables 2.80M 0.90M 1.40M - 0.03M
Long term debt 9.33M 9.16M - 4.25M 7.25M
Inventory - - - - -
Accounts payable 2.30M 1.53M 3.24M 2.75M 3.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.27100M -8.03200M -1.78900M 0.05M 0.33M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00700M 0.00700M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - -568.80800M -432.96800M -302.50200M -212.87700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.40M 3.50M 3.52M 1.56M 2.33M
Deferred long term asset charges - - - - -
Non current assets total 16.45M 9.88M 11.76M 9.92M 2.37M
Capital lease obligations 7.87M 4.87M 6.88M 7.73M -
Long term debt total - 9.16M - 4.25M 7.25M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 32.63M -125.68800M -97.76500M -46.32500M -79.30000M
Change to liabilities -0.61800M -2.53800M 5.89M 1.07M 0.25M
Total cashflows from investing activities 32.63M -126.83500M -99.93600M -46.32500M -79.30000M
Net borrowings 9.43M -7.86100M -0.25000M -0.25000M -0.62300M
Total cash from financing activities 38.56M -3.43500M 469.33M 111.10M 132.64M
Change to operating activities -2.18000M -0.70600M 0.71M -0.99200M -0.72700M
Net income -135.84000M -130.46600M -89.62500M -63.14000M -60.44700M
Change in cash -38.87000M -234.82100M 299.57M 10.02M 4.69M
Begin period cash flow 90.88M 325.70M 26.14M 16.12M 11.43M
End period cash flow 52.01M 90.88M 325.70M 26.14M 16.12M
Total cash from operating activities -110.06200M -104.55100M -69.83000M -54.76000M -48.65500M
Issuance of capital stock 24.72M 0.00000M 459.33M 108.17M 132.17M
Depreciation 0.76M 0.56M 0.19M -1.10300M 0.01000M
Other cashflows from investing activities - - - -46.32500M -79.30000M
Dividends paid - - - - -
Change to inventory - - - - -0.44300M
Change to account receivables - - - 0.21M -0.00800M
Sale purchase of stock 29.14M - 459.33M 108.17M 132.17M
Other cashflows from financing activities 13.84M 3.81M 10.25M 2.94M 1.72M
Change to netincome 26.39M 24.19M 12.81M 9.41M 9.15M
Capital expenditures 0.63M 1.15M 2.17M 2.17M 2.17M
Change receivables - - - 0.21M -0.00800M
Cash flows other operating -2.36400M -0.68600M 0.49M -1.20200M 4.14M
Exchange rate changes - - - - -
Cash and cash equivalents changes -38.87000M -234.82100M 299.57M 10.02M 4.69M
Change in working capital -2.98200M -3.22400M 6.38M 0.07M 4.38M
Stock based compensation 26.32M 23.58M 12.81M 9.41M 8.65M
Other non cash items 1.68M 0.40M 0.41M -1.10300M 0.18M
Free cash flow -110.68800M -105.69800M -72.00100M -54.76000M -48.65500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
KURA
Kura Oncology Inc		 0.12 1.33% 8.77 - - - 3.73 -7.1648
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology Inc

12730 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Troy Edward Wilson J.D., Ph.D. Chairman, CEO, Pres & Principal Financial Officer 1969
Ms. Kathleen Ford Chief Operating Officer 1947
Dr. Marc Grasso M.D. Advisor 1974
Ms. Kirsten Flowers Chief Commercial Officer & Chief Corp. Strategy Officer 1975
Dr. Stephen Dale M.D. Chief Medical Officer 1972
Mr. Thomas Doyle Principal Accounting Officer & Sr. VP of Fin. and Accounting 1971
Mr. Pete De Spain Sr. VP of Investor Relations & Corp. Communications NA
Mr. James E. Basta J.D., Esq. Chief Compliance Officer & Corp. Sec. 1966
Ms. Teresa Brophy Bair Esq., J.D. Chief Legal Officer & Corp. Sec. 1971
Dr. Roger Bakale Ph.D. VP and Head of CMC, Clinical & Commercial Manufacturing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions